Chimeric Antigen Receptor Therapy for Cancer

摘要: Improved outcomes for patients with cancer hinge on the development of new targeted therapies acceptable short-term and long-term toxicity. Progress in basic, preclinical, clinical arenas spanning cellular immunology, synthetic biology, cell-processing technologies has paved way applications chimeric antigen receptor– based therapies. This form immunotherapy merges exquisite targeting specificity monoclonal antibodies potent cytotoxicity persistence provided by cytotoxic T cells. Although this field is still its infancy, trials have already shown clinically significant antitumor activity neuroblastoma, chronic lymphocytic leukemia, B cell lymphoma, a variety other adult pediatric malignancies are under way. Ongoing work focused identifying optimal tumor targets elucidating manipulating both cell- host-associated factors to support expansion genetically engineered cells vivo. The potential target essentially any tumor-associated cell-surface which antibody can be made opens up an entirely arena therapy cancer.